BIRC5 and cancer: Finally a recent patent application discloses a series of small molecule compounds as reversible inhibitors of the CRM1 driven export of Hiv-Ref-GFP and Survivin-GFP for the treatment or prophylaxis of cancer or viral diseases (EP 2 431 364 A1).